FRI0201 Etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using canadian claims-level data

BackgroundEtanercept is a soluble TNF receptor (humanized protein) indicated for the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Limited information exists on the factors associated